DDW’s Megan Thomas speaks with Dr Maria-Magdalena Patru, Scientific Partner at Roche Diagnostics US, about how advances in Alzheimer’s disease (AD), particularly blood-based biomarkers (BBM), can enable earlier, more accurate, and accessible detection of the disease, supporting timely treatment and improved patient outcomes. MT: Why is improving AD diagnostics crucial for researchers trying to understand […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!